Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
NCT04592913Phase 3Active, not recruiting
- Lead sponsor
- AstraZeneca (Industry)
- Enrollment
- 957 (actual)
- Start date
- 17 Nov 2020
- Primary completion
- 20 Dec 2024 (actual)
- Study completion
- 27 Sep 2027
- Last update posted
- 24 Dec 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Durvalumab Drug
- FLOT chemotherapy Drug
Conditions and primary outcome
- Gastrointestinal Neoplasms
- Esophagogastric Junction
Primary outcome
Event-free survival (EFS) (Up to 5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
5 on PubMedPerioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet (London, England) · 2026 Sep 19
PubMed 42716074 (opens in a new tab)DOI 10.1016/S0140-6736(26)01254-7 (opens in a new tab)
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
The New England journal of medicine · 2025 Jul 17
PubMed 40454643 (opens in a new tab)DOI 10.1056/NEJMoa2503701 (opens in a new tab)
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
Future oncology (London, England) · 2022 Jun
PubMed 35535555 (opens in a new tab)DOI 10.2217/fon-2022-0093 (opens in a new tab)
The current management and biomarkers of immunotherapy in advanced gastric cancer.
Medicine · 2022 May 27
PubMed 35623069 (opens in a new tab)DOI 10.1097/MD.0000000000029304 (opens in a new tab)
Top advances in esophageal/gastroesophageal junction cancers in 2021.
Cancer · 2022 May 15
PubMed 35179774 (opens in a new tab)DOI 10.1002/cncr.34140 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT04592913 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.